These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23695427)

  • 1. Moving towards disease modification in inflammatory bowel disease therapy.
    Allen PB; Peyrin-Biroulet L
    Curr Opin Gastroenterol; 2013 Jul; 29(4):397-404. PubMed ID: 23695427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab for the treatment of inflammatory bowel disease.
    Wasan SK; Kane SV
    Expert Rev Gastroenterol Hepatol; 2011 Dec; 5(6):679-84. PubMed ID: 22017695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
    Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
    J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing vedolizumab to clinical practice: who, when, and how?
    Bryant RV; Sandborn WJ; Travis SP
    J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
    Rutgeerts P; Vermeire S; Van Assche G
    Gut; 2007 Apr; 56(4):453-5. PubMed ID: 17369375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
    Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Promising Combo Therapy in Inflammatory Bowel Diseases Refractory to Anti-TNF Agents: Cyclosporine Plus Vedolizumab.
    Szántó K; Molnár T; Farkas K
    J Crohns Colitis; 2018 Apr; 12(5):629. PubMed ID: 29272353
    [No Abstract]   [Full Text] [Related]  

  • 13. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
    Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.
    Armuzzi A; Gionchetti P; Daperno M; Danese S; Orlando A; Lia Scribano M; Vecchi M; Rizzello F;
    Dig Liver Dis; 2016 Apr; 48(4):360-70. PubMed ID: 26821929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.
    Oussalah A; Roblin X; Laharie D; Filippi J; Flamant M; Faure P; Phelip JM; Bigard MA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(8):854-63. PubMed ID: 19764940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
    Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J
    Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases.
    De Simone C; Sollena P; Coco V; Caldarola G
    G Ital Dermatol Venereol; 2013 Apr; 148(2):175-84. PubMed ID: 23588143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease.
    Florholmen J
    Scand J Gastroenterol; 2015 Jan; 50(1):43-52. PubMed ID: 25523555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximizing the effect of biologics in inflammatory bowel disease.
    Souto Rodriguez R; Swoger JM; Barreiro-De Acosta M; Regueiro M
    Minerva Gastroenterol Dietol; 2012 Jun; 58(2):101-22. PubMed ID: 22643594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
    Peyrin-Biroulet L
    Am J Gastroenterol; 2013 May; 108(5):859-60. PubMed ID: 23644972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.